US · Healthcare · Healthcare Plans
EPS came in at 0.31 against a street estimate of 0.27 — a beat of 14.8%.
Analysts rate Progyny Inc a strong buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $34.42.
CONFIDENT Q2 delivered record revenue, gross profit, and adjusted EBITDA with 180bp margin expansion. Strong selling season momentum with 1M+ life target on track. Summer seasonality noted but expected to normalize by fall. Q2 2026 No geographic breakdown provided. International expansion commentary limited to multinational employer strategies; not quantified. Analysts pressed summer seasonality, visibility into 2027 lives, and Select/channel materiality. Management clarified: seasonal softness typical but slightly elevated; good pipeline visibility; brownfield wins driven by cost inflation; Select/channels immaterial to 2027. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.99% |
| FMR Inc | 9.05% |
| Vanguard Portfolio Management, LLC | 6.49% |
| Vanguard Capital Management, LLC | 4.15% |
| State Street Corp | 3.91% |
| Ameriprise Financial Inc | 3.57% |
| Geode Capital Management, LLC | 2.54% |
| Citadel Advisors Llc | 2.31% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $341,254,000, up from $313,346,000 in the third quarter of 2025. • Nine-month 2026 revenue was $1, | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $341.3 million, up 8.9% from $313.3 million. • Gross profit was $83.7 million, up 15% from $72.8 m | 2026-11-04 |
| Quarterly report · Q2 2026 PROGYNY, INC. — Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $350.5 million, up 5.3% from $332.9 million in Q2 2025 • Revenue (H1 | 2026-08-07 |
| Results announced · Q3 2026 PROGYNY, INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue: $350.5 million, up 5.3% YoY ($332.9 million in Q2 2025); excluding lost client | 2026-08-06 |
| Charter / bylaws change · Q2 2026 PROGYNY, INC. (PGNY) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 21, 2026 with 72,003,873 shares represented (91.92% of shares ent | 2026-05-27 |
| Company announcement · Q2 2026 PROGYNY, INC. (PGNY) - 8-K FILING SUMMARY Date: May 26, 2026 --- HEADLINE NUMBERS • Board approved share repurchase program authorization of $200 m | 2026-05-26 |
| Quarterly report · Q1 2026 PROGYNY, INC. — Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue: $328.5 million (Q1 2026) vs. $324.0 million (Q1 2025) — up 1.4% yea | 2026-05-08 |
| Results announced · Q2 2026 PROGYNY, INC. — Q1 2026 FINANCIAL SUMMARY --- HEADLINE NUMBERS • Revenue: $328.5 million (up 1.4% YoY); excluding the large client who didn't renew | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board approves $200 million share repurchase program Progyny, Inc. announced a $200 million share repurchase program approved by its Board of Directors. The company will buy back its own stock using cash on hand through open market purchases, | 2026-05-26 |
| Updated financial guidance for Q4 2025 and full year 2025 Progyny, Inc. issued an 8-K filing on January 12, 2026, announcing an update to its previously issued financial guidance for Q4 2025 and the full year 2025. The company released a press rele | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Progyny Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.